Clinical Cancer Research Versailles No Abst Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matsumura, T.
Right arrow Articles by Mitamura, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matsumura, T.
Right arrow Articles by Mitamura, K.
Clinical Cancer Research Vol. 7, 594-599, March 2001
© 2001 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Frequent Down-Regulation of E-cadherin by Genetic and Epigenetic Changes in the Malignant Progression of Hepatocellular Carcinomas1

Takuya Matsumura, Reiko Makino2 and Keiji Mitamura

Second Department of Internal Medicine, Showa University School of Medicine, Tokyo, 142-8666, Japan

E-cadherin mediates cell-cell adhesion by associating with catenins. Loss of E-cadherin function by genetic or epigenetic alteration of the E-cadherin gene (CDH1) leads to tumorigenesis. To study the involvement of E-cadherin dysfunction in liver tumorigenesis, we examined the allelic loss and methylation of 5'-CpG sites of CDH1 in hepatocellular carcinomas (HCCs). Loss of heterozygosity (LOH) of CDH1 and adjacent 16q22-23 loci was observed in 13 of 30 (43%) HCCs. Methylation of the 5'-CpG of CDH1 was analyzed by Southern blot hybridization, and hypermethylation was observed in 8 of the 24 (33%) HCCs examined. The amount of E-cadherin mRNA was analyzed by RNase protection assay, and a decrease in E-cadherin mRNA was observed in 10 of the 23 cases examined. A reduction in E-cadherin was found in 10 of 21 HCCs using immunoblot analysis. The amount of E-cadherin was comparable to that of E-cadherin mRNA. Down-regulation of E-cadherin was common in cases with LOH but rare in cases with methylated promoter. These results suggest that hypermethylation of the CDH1 promoter is present in a small cell population in the tumor, thus the methylation status is liable to vary according to individual cell condition. Hypermethylation was observed in early stage HCCs, whereas LOH was found frequently in more malignant tumors. Down-regulation of E-cadherin is closely related to the progression of HCCs and is stably induced by LOH of CDH1.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
W. C. Reinhold, M. A. Reimers, A. K. Maunakea, S. Kim, S. Lababidi, U. Scherf, U. T. Shankavaram, M. S. Ziegler, C. Stewart, H. Kouros-Mehr, et al.
Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells
Mol. Cancer Ther., February 1, 2007; 6(2): 391 - 403.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
A. N.M. Fischer, B. Herrera, M. Mikula, V. Proell, E. Fuchs, J. Gotzmann, R. Schulte-Hermann, H. Beug, and W. Mikulits
Integration of Ras subeffector signaling in TGF-{beta} mediated late stage hepatocarcinogenesis
Carcinogenesis, May 1, 2005; 26(5): 931 - 942.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Fiorentino, A. Altimari, M. Ravaioli, E. Gruppioni, E. Gabusi, B. Corti, M. Vivarelli, P.-P. Bringuier, J.-Y. Scoazec, W. F. Grigioni, et al.
Predictive Value of Biological Markers for Hepatocellular Carcinoma Patients Treated with Orthotopic Liver Transplantation
Clin. Cancer Res., March 1, 2004; 10(5): 1789 - 1795.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
M. A. Davis, R. C. Ireton, and A. B. Reynolds
A core function for p120-catenin in cadherin turnover
J. Cell Biol., November 10, 2003; 163(3): 525 - 534.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. Nishimura, T. Saito, H. Yamasaki, and R. Kudo
Suppression of gap junctional intercellular communication via 5' CpG island methylation in promoter region of E-cadherin gene in endometrial cancer cells
Carcinogenesis, October 1, 2003; 24(10): 1615 - 1623.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
B. Yang, M. Guo, J. G. Herman, and D. P. Clark
Aberrant Promoter Methylation Profiles of Tumor Suppressor Genes in Hepatocellular Carcinoma
Am. J. Pathol., September 1, 2003; 163(3): 1101 - 1107.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
S. D. Safford, D. Goyeau, A. J. Freemerman, R. Bentley, M. L. Everett, P. E. Grundy, and M. A. Skinner
Fine Mapping of Wilms' Tumors With 16q Loss of Heterozygosity Localizes the Putative Tumor Suppressor Gene to a Region of 6.7 Megabases
Ann. Surg. Oncol., March 1, 2003; 10(2): 136 - 143.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
W.-M. Tong, U. Cortes, M. P. Hande, H. Ohgaki, L. R. Cavalli, P. M. Lansdorp, B. R. Haddad, and Z.-Q. Wang
Synergistic Role of Ku80 and Poly(ADP-ribose) Polymerase in Suppressing Chromosomal Aberrations and Liver Cancer Formation
Cancer Res., December 1, 2002; 62(23): 6990 - 6996.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
R. C. Ireton, M. A. Davis, J. van Hengel, D. J. Mariner, K. Barnes, M. A. Thoreson, P. Z. Anastasiadis, L. Matrisian, L. M. Bundy, L. Sealy, et al.
A novel role for p120 catenin in E-cadherin function
J. Cell Biol., November 7, 2002; 159(3): 465 - 476.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
J. Gotzmann, H. Huber, C. Thallinger, M. Wolschek, B. Jansen, R. Schulte-Hermann, H. Beug, and W. Mikulits
Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-{beta}1 and Ha-Ras: steps towards invasiveness
J. Cell Sci., March 15, 2002; 115(6): 1189 - 1202.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.